Home/Pipeline/DecisionDx-Melanoma (i31-SLNB)

DecisionDx-Melanoma (i31-SLNB)

Cutaneous Melanoma (Stage I-III)

Commercial/Ongoing ValidationActiveNCT04370938

Key Facts

Indication
Cutaneous Melanoma (Stage I-III)
Phase
Commercial/Ongoing Validation
Status
Active
Company

About Castle Biosciences

Castle Biosciences is a mission-driven company focused on transforming disease management by applying precision genomics to high-stakes clinical decisions. Since its 2008 founding, it has built a commercially successful portfolio of proprietary tests, supported by over 150 peer-reviewed publications and more than 300,000 test reports delivered. Its strategy centers on addressing critical unmet needs in dermatologic, ocular, and gastrointestinal oncology through its multi-analyte GEP platform, driving growth via clinical validation, payer coverage, and market penetration.

View full company profile